Chemistry:Remibrutinib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H27F2N5O3 |
| Molar mass | 507.542 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Remibrutinib is a small molecule drug that acts as a Bruton's tyrosine kinase (BTK) inhibitor. It is in development for the treatment of chronic spontaneous urticaria.[1][2] In November 2023, Novartis announced that the compound "demonstrated clinically meaningful and statistically significant reduction in urticaria activity vs placebo" in a Phase III trial.[3]
References
- ↑ Maurer, Marcus; Berger, William; Giménez-Arnau, Ana; Hayama, Koremasa; Jain, Vipul; Reich, Adam; Haemmerle, Sibylle; Lheritier, Karine et al. (December 2022). "Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria". The Journal of Allergy and Clinical Immunology 150 (6): 1498–1506.e2. doi:10.1016/j.jaci.2022.08.027. ISSN 1097-6825. PMID 36096203.
- ↑ Maurer, Marcus; Giménez-Arnau, Ana; Jain, Vipul; Tillinghast, Jeffrey; Tolcachier, Alberto; Nigen, Simon; Hayam, Koremasa; Lheritier, Karine et al. (February 2022). "Remibrutinib Treatment Improves Quality of Life in Patients with Chronic Spontaneous Urticaria". Journal of Allergy and Clinical Immunology 149 (2): AB179. doi:10.1016/j.jaci.2021.12.589.
- ↑ "Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2" (in en). https://www.novartis.com/news/media-releases/novartis-data-show-potential-remibrutinib-oral-treatment-chronic-spontaneous-urticaria-providing-significant-symptom-improvement-early-week-2.
 |  |
